ASCO GU 2017: Individual patient level meta-analysis of the performance of the Decipher® genomic classifier in high-risk men post-prostatectomy to predict development of metastatic disease.

Orlando, Florida USA (UroToday.com) This study is the first meta-analysis of the performance of the Decipher® genomic classifier in prostate cancer patients post-RP. The aim was to investigate the performance of Decipher® in subgroups classified by pre-RP PSA, RP Gleason score, surgical margins, extraprostatic extension, seminal vesical invasion, and lymph node invasion. The study found a lack of heterogeneity in the 5 studies reported. In addition, Decipher® provided important prognostic information in each of the above mentioned subgroups and independently added prognostic benefit to the commonly used clinicopathologic variables.

This study confirmed the findings of the previous studies on the efficacy of Decipher® and further validated in men post-RP.

First Author: Daniel Spratt

at the 2017 Genitourinary Cancers Symposium - February 16 - 18, 2017 – Orlando, Florida USA

Login